Thrombosis and Haemostasis, Inhaltsverzeichnis Thromb Haemost 1997; 78(01): 214-219DOI: 10.1055/s-0038-1657529 Clinical trials with anti IIb/IIIa inhibitors in acute coronary syndromes Schattauer GmbH Stuttgart Conjunctive Use of Platelet Glycoprotein IIb/IIIa Antagonists and Thrombolytic Therapy for Acute Myocardial Infarction David J Moliterno 1 Department of Cardiology, Cleveland, OH, USA , Eric J Topol 2 The Joseph J. Jacobs Center for Thrombosis and Vascular Biology, The Cleveland Clinic Foundation, Cleveland, OH, USA › Institutsangaben Artikel empfehlen Abstract als PDF herunterladen Artikel einzeln kaufen PDF (1111 kb) Referenzen References 1 The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. New England Journal of Medicine 1993; 329: 673-682 2 AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988; 01: 842-847 3 Gruppo Italiano per lo Studio della Sopravvivenza nelFInfarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 01: 397-402 4 Wilcox RG, von derLippeG, Olsson CG, Jensen G, Skene AM, Hampton JR. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Lancet 1988; 11: 525-530 5 Weaver WD, Cerqueira M, Hallstrom AP, Litwin PE, Martin JS, Kudenchuk PJ, Eisenberg M. Prehospital-initiated vs hospital-initiated thrombolytic therapy: The Myocardial Infarction Triage Intervention Trial. JAMA 1993; 270: 1211-1216 6 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction; ISIS-2. Lancet 1988; 02: 349-360 7 Topol EJ, Califf RM, Vandormael M, Grines CL, George BS, Sanz ML, Wall T, O’Brien M, Schwaiger M, Aguire FV, Young GS, Popma JJ, Sigmon KN, Lee KL, Ellis SG. and the Thrombolysis and Angioplasty in Myocardial Infarction-6 Study Group A randomized trial of late reperfusion therapy for acute myocardial infarction. Circulation 1992; 85: 2090-2099 8 Simoons ML, Serruys PW, van denBrandM, Res J, Verheught FWA, Krauss XH, Remme WJ, Bar F, de ZwaanC, van derLaarseA, Vermeer F, Lubsen J. Early thrombolysis in acute myocardial infarction: Limitation of infarct size and improved survival. Journal of American College of Cardiology 1986; 07: 717-728 9 White HD, Norris RM, Brown MA, Takayama M, Maslowski A, Bass NM, Ormiston JA, Whitlock T. Effect of intravenous strepotokinase on left ventricular function and early survival after acute myocardial infarction. New England Journal of Medicine 1987; 317: 850-855 10 Lincoff AM, Topol EJ. Illusion of reperfusion: does anyone achieve optimal reperfusion during acute myocardial infarction?. Circulation 1993; 87: 1792-1805 11 Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Brunwald E. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987; 76: 142-154 12 The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-ar- tery patency, ventricular function, and survival after myocardial infarction. New England Journal of Medicine 1993; 329: 1615-1622 13 Smalling RW, Bode C, Kalbfleisch J, Sen S, Limbourg P, Forycki F, Habib G, Feldman R, Hohnloser S, Seals A. and the RAPID Investigators More rapid complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995; 91: 2725-2732 14 Bode C, Smalling RW, Berg G, Burnett C, Lorch G, Kalbfleisch JM, Chernoff R, Christie LG, Feldman RL, Seals AA, Weaver WD. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasmongen activator) in patients with acute myocardial infarction. Circulation 1996; 94: 891-898 15 Cannon CP, McCabe CH, Gibson CM, Ghali M, Sequeira RF, McKendall GR, Breed J, Modi NB, Fox NL, Tracy RP, Love TW, Braunwald EB. and the TIMI 10A Investigators TNK- tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis In Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation 1997; 95: 351-356 16 Granger CB, Califf RM, Topol EJ. Thrombolytic therapy for acute myocardial infarction. Drugs 1992; 44: 293-325 17 Ohman EM, Califf RM, Topol EJ, Candela R, Abbottsmith C, Ellis S, Sigmon KN, Kereiakes D, George B, Stack R. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990; 82: 781-791 18 Fitzgerald DJ, Catella F, Roy L, Fitzgerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. New England Journal of Medicine 1988; 77: 142-150 19 Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers AD. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988; 72: 616-620 20 Merlini PA, Bauer KA, Oltrona L, Ardissino D, Spinola A, Cattaneo M, Broccolino M, Mannucci PM, Rosenburg RD. Thrombin generation and activity during thrombolysis and concomitant heparin therpay in patients with acute myocardial infarction. Journal of American College of Cardiology 1995; 25: 203-209 21 Chesebro H, Fuster V. Dynamic thrombosis and thrombolysis. Role of anti thrombins. Circulation 1991; 83: 1815-1817 22 Coller BS. Platelets and thrombolytic therapy. New England Journal of Medicine 1990; 322: 33-42 23 Fitzgerald DJ, Wright F, Fitzgerald GA. Increased thromboxane biosynthesis during coronary thrombolysis. Circulation Research 1989; 65: 83-94 24 Coller BS. The role of platelets in arterial thrombosis and the rationale for blockade of platelet GP Ilb/IIIa receptors as antithrombotic therapy. European Heart Journal 1995; 16 (Suppl L) 11-15 25 Golino P, Ashton JH, Glas-Greenwalt P, McNatt J, Buja LM, Willerson JT. Mediation of reocclusion by thromboxane A2 and serotonin after trhombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. Circulation 1988; 77: 678-684 26 Schumacher WA, Buda AJ, Lucchesi BR. Streptokinase thrombolysis in experimental coronary artery thrombosis: Pattern of reflow and effect of a stenosis. International Journal of Cardiology 1984; 06: 615-627 27 Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein Ilb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332 (23) 1553-1559 28 The EPIC Investigators. Use of a monoclonal antibody directed against the glycoprotein Ilb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961 29 Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI, Smith JE, Worley SJ, Miller JA, Joseph DM, Sigmon KN, Kitt MM, du MeeCP, Califf RM, Topol EJ. for the IMPACT Investigators Multicenter, randomized, double-blind, placebo-controlled trial of platelet integrin glycoprotein Ilb/IIIa blocker Integrilin in elective coronary intervention. Circulation 1995; 91: 2151-2157 30 Jang IK, Gold HK, Ziskind AA, Fallon JT, Holt RE, Leinbach RC, May JW, Collen D. Differential sensitivity of erythrocyte- rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator: a possible explanation for resistance to coronary thrombolysis. Circulation 1989; 79: 920-928 31 Yasuda T, Gold HK, Fallon J, Leinbach RC, Guerrero JL, Scudder LE, Kanke M, Shealy D, Ross MJ, Collen D, Coller BS. A monoclonal antibody against the platelet GP Ilb/IIIa receptor prevents coronary artery reocclusion following reperfusion with recombinant tissue-type plasminogen activator in dogs. Journal of Clinical Investigation 1988; 81: 1284-1291 32 Yasuda T, Gold HK, Leinbach RC, Sai to, Guerrero TJL, Jang I-K, Holt R, Fallon JT, Collen D. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody. Journal of American College of Cardiology 1990; 16: 1728-1735 33 Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero JL, Leinbach RC, Ziskind AA, Collen D. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GP Ilb/IIIa antibody in a canine preparation. Circulation 1988; 77: 670-677 34 Kohmura C, Gold HK, Yasuda T, Holt R, Nedelman MA, Guerrero JL, Weisman HF, Collen D. A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/ Ilia receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons. Arteriosclerosis & Thrombosis 1993; 13: 1837-1842 35 Lucchessi BR, Rote WE, Driscoll EM, Mu D-X. Prevention of thrombosis and rethrombosis and enhancement of the thrombolytic actions of recombinant tissue-type plasminogen activator in the canine heart by DMP728, a glycoprotein IIb/IIIa antagonist. British Journal of Pharmacology 1994; 113: 1333-1343 36 Yasuda T, Gold HK, Kohmura C, Guer rero, JL YaoitaH, Fallon JT, Bunting S, Collen D. Intravenous and endobronchial administration of G4120, a cyclic Arg-Gly-Asp-containing platelet GPIIb/IIIa receptor- blocking pentapeptide enhances and sustains coronary arterial thrombolysis with rt-PA in a canine preparation. Arteriosclerosis & Thrombosis 1993; 13: 738-747 37 Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, Weisman H, Schaible T, Topol EJ. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. kJournal of American College of Cardiology 1993; 22: 381-389 38 Ohman EM, Kleinman NS, Gacioch G, Worley SJ, Navetta FI, Talley JD, Anderson HV, Ellis SG, Cohen MD, Spriggs D, Miller M, Kereiakes D, Yakubov S, Kitt MM, Sigmon KN, Califf RM, Krucoff MW, Topol EJ. for the IMPACT-AMI Investigators Combined accelerated tissue-plasminogen activator and glycoprotein Ilb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: results of a randomized, placebo-controlled, dose-ranging trial. Circulation 1997; 95: 846-854 39 Moliterno DJ, Harrington RA, Califf RM, Rapold HJ, Topol EJ. for the PARADIGM Investigators Randomized, placebo-controlled study of Lamifiban with thrombolytic therapy for the treatment of acute myocardial infarction: rationale and design for the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) study. Journal of Thrombosis and Thrombolysis 1996; 02: 165-169 40 Moliterno DJ, Harrington RA, Krucoff MW, Armstrong PW, Van deWerfF, Kristinsson A, Hui W, Paraschos A, Bhapkar M, Rames A, Topol EJ. for the PARADIGM Investigators More complete and stable reperfusion with platelet Ilb/IIIa antagonism plus thrombolysis for AMI: The PARADIGM trial. Circulation 1996; 94: 001-553 41 Cigarroa JE, Ferrell MA, Collen DJ, Leinbach RC. Enhanced endogenous coronary thrombolysis during acute myocardila infarction follwoing selective platelet receptor blockade with ReoPro. Circulation 1996; 94: 001-553
